Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748 · Verona Phase 3Active, not recruiting
- Lead sponsor
- AbbVie (Industry)
- Enrollment
- 531 (actual)
- Start date
- 10 Sep 2020
- Primary completion
- Jul 2027 (estimated)
- Study completion
- 1 Jul 2027
- Last update posted
- 6 May 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Venetoclax Drug
- Azacitidine Drug
- Placebo Drug
Conditions and primary outcome
- Myelodysplastic Syndrome (MDS)
Primary outcome
Overall survival (OS) (Up To 5 Years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
2 on PubMedTherapy of high-risk myelodysplastic syndromes.
Bone marrow transplantation · 2026 May
PubMed 41792302 (opens in a new tab)DOI 10.1038/s41409-026-02821-4 (opens in a new tab)
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
The Lancet. Haematology · 2024 Jan
PubMed 38065202 (opens in a new tab)DOI 10.1016/S2352-3026(23)00343-5 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04401748 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.